Graft-versus-host disease prophylaxis with antithymocyte globulin in patients receiving stem cell transplantation from unrelated donors: An observational retrospective single-center study

Data from a retrospective study of patients with hematologic malignancies who received 5 mg/kg anti-thymocyte globulin (ATG) GVHD prophylaxis before undergoing unrelated donor allogeneic HSCT showed that cumulative incidence of grade II-IV acute GVHD was 29.9% and moderate to severe chronic GVHD was 29.8%. The cumulative incidence of nonrelapse mortality at 1, 2, and 3 years post-transplant was 18.2%, 19.6%, and 20.2%, respectively, while the cumulative incidence of relapse incidence at 1, 2, and 3 years post-transplant was 17.8%, 21.0%, and 21.6%, respectively.